Companies / BOC Sciences / Nemolizumab
BOC Sciences

Nemolizumab | BOC Sciences

Nemolizumab is an anti-IL31 receptor A monoclonal antibody that inhibits the IL31 signaling. Nemolizumab has been developed for the treatment of atopic dermatitis.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More